Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of BTX-A-HAC NG for glabellar lines
2013-002321-34Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2014
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glabellar furrowing comparing Dysport NG with Placebo (2 arms). Primary endpoint: Day 29 responder rate by ILA at maximum frown. Started Sep 2014; status: completed.
02
Drugs
corabotase
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2013-002321-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002321-34.